To conduct a meta-analysis of the efficacy and safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease (CHD) with hyperlipidemia (HPL).

The literatures were retrieved from China HowNet, Wanfang Database, Weipu Database, China Biomedical Database and PubMed from the database establishment to January 2020 and those related to the rosuvastatin and atorvastatin in the treatment of coronary heart disease with hyperlipidemia were screened. In the clinical study, the experimental group was treated with rosuvastatin and the control group was treated with atorvastatin. For the extracted data and quality evaluation of the included literature, meta analysis was performed using Revman5.3 software. Heterogeneity among studies was judged by χ2 test. The odds ratio (OR) and 95% confidence interval (95% CI) were used to evaluate the outcome indicators, and the continuous variable was used to calculate the average difference (MD). A funnel chart was used to assess publication bias.

A total of 1487 patients were included in the standard-matched literature, including 752 patients in the test group and 735 patients in the control group. Compared with the control group, patient's clinical symptom in the test group were significantly improved (OR=5.88, 95%CI: 3.31~10.43, P<0.05); serum total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C) were reduced(MD=-0.28, 95%CI: -0.31 to -0.24, P<0.05; MD=-0.36, 95%CI: -0.39 to -0.33, P <0.05; MD=-0.65, 95% CI: -0.69~-0.61, P <0.05). At the same time, the decline of HDL-C and NO was inhibited (MD=0.30, 95% CI: 0.28 ~ 0.33, P<0.05; MD=13.19, 95%CI: 11.70-14.68, P<0.05).

Rosuvastatin has higher clinical efficacy and better lipid-lowering effect in treating CHD combined with HPL.